Brukinsa (zanubrutinib) is used to treat mantle cell lymphoma in adults who have received at least one prior treatment for this condition.
Brukinsa was approved by the US Food and Drug Administration (FDA) on an "accelerated" basis. In clinical studies, some people responded to this medicine, but further studies are needed.
It is not known if Brukinsa is safe and effective in children.
